IgA antibodies are also expected to be combined with IgG to develop homotypic cross-antibodies containing both IgG and IgA Fc domain residues, so that they can not only activate neutrophils- and macrophage-mediated tumor killing but also play a role in complement-dependent cytotoxicity, and their kinetic characteristics can be improved additionally. This evidence concerns the gene CD79A and neoplasm.